After creating two new R&D units and simultaneous commercial units to run alongside them, with a new and controversial scientist taking up the cancer research reins, the changes and departures keep coming from AstraZeneca.
Today, Bloomberg reports that Sean Bohen, M.D., Ph.D., CMO and EVP of global medicines development, is out the door, following closely in the footsteps of Bahija Jallal, Ph.D., former head of its biologics arm MedImmune, now CEO of Immunocore, as well as portfolio strategy chief Mark Mallon.
The R&D and commercial changes announced last week were a reaction to these departures and saw José Baselga, M.D., Ph.D., run its newly formed cancer-focused unit. He had been physician-in-chief at Memorial Sloan-Kettering but was forced out in the fall over allegations he was paid renumeration from biopharmas that were not properly disclosed.
Mene Pangalos, Ph.D., who was previously responsible for the company’s Innovative Medicines and Early Development Biotech Unit, now runs a second, nononcology unit.
Bohen now becomes the latest high-profile executive to leave the company. The British-based pharma confirmed to FierceBiotech that Bohen will be leaving but won’t be going until a successor is found. The former Genentech executive did not say where he would be setting his sights on next, but the company said he was key in the company’s growth, and that he will leave “eventually,” although a direct successor is not yet being sought.
This comes amid a mixed time for AstraZeneca, with its CEO Pascal Soriot also endlessly speculated to be heading for the exit, something however he continuously denies, and a plethora of trial setbacks over the years, with cancer becoming a brighter spot but still being hit by some late-stage failures.
By Ben Adams
Source: Fierce Biotech
Monday, the French pharma giant officially moved into its new global home base in Paris, dubbed La Maison Sanofi. The 9,000-square-meter (about 96,875-square-foot) facility comprises two historic buildings and will host around 500 employees, the company explained in a release.
On the first day of the new year, former Sandoz chief Richard Francis will take the reins from Schultz, who is hanging up his CEO hat to retire on Dec. 31, Teva said Monday. The news comes a little more than two weeks after Teva publicly said it was looking for Schultz’s replacement.
General Electric Co. set the terms for the spinoff of its healthcare division, putting an initial value of roughly $31 billion on the soon-to-be-public company. The Boston conglomerate plans to split into three separate public companies by early 2024. Following the healthcare spinoff, it plans to separate its aerospace business from its power and renewable-energy units.